However, several questions have been raised including how to enrich the responsive TNBC population, how to assess PD-L1 positivity and thus patients' response to atezolizumab, whether PD-L1 expression should be tested in the tumor or immune cells, if nab-paclitaxel is the best chemotherapy to use and if atezolizumab monotherapy could have been beneficial for a certain subset of patients without chemotherapy 129. The gene discussed is CD274; the disease is neoplasm.